Beigene Ltd - ESG Rating & Company Profile powered by AI
The webpage is a free ESG report covering Beigene Ltd. This report of Beigene Ltd is assembled by All Street Sevva using proprietary artificial intelligence. Other corporations in the scoring industry group for Beigene Ltd are displayedin the table.
Beigene Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.7; made up of an environmental score of 4.0, social score of 5.0 and governance score of 8.0.
5.7
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 541 | Wntresearch AB | 5.8 | High |
| 541 | Zenotech Laboratories Ltd | 5.8 | High |
| 579 | Beigene Ltd | 5.7 | High |
| 579 | Caplin Point Laboratories Ltd | 5.7 | High |
| 579 | Biotest AG | 5.7 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Beigene Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Beigene Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Beigene Ltd report the average age of the workforce?
Sign up for free to unlockDoes Beigene Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Beigene Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Beigene Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Beigene Ltd offer flexible work?
Sign up for free to unlockDoes Beigene Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Beigene Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Beigene Ltd conduct supply chain audits?
Sign up for free to unlockDoes Beigene Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Beigene Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Beigene Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Beigene Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Beigene Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Beigene Ltd disclose water use targets?
Sign up for free to unlockDoes Beigene Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Beigene Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Beigene Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Beigene Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Beigene Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Beigene Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Beigene Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Beigene Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Beigene Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Beigene Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Beigene Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Beigene Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Beigene Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Beigene Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Beigene Ltd disclose its waste policy?
Sign up for free to unlockDoes Beigene Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Beigene Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Beigene Ltd disclose energy use targets?
Sign up for free to unlockDoes Beigene Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Beigene Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Beigene Ltd
These potential risks are based on the size, segment and geographies of the company.
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.